We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Biodegradable Balloon to Revolutionize Rectal Protection from Toxicity during Prostate Cancer Radiation Therapy

By MedImaging International staff writers
Posted on 30 Aug 2023
Print article
Image: The BioProtect Balloon Spacer protects adjacent healthy tissues from harmful radiation (Photo courtesy of BioProtect)
Image: The BioProtect Balloon Spacer protects adjacent healthy tissues from harmful radiation (Photo courtesy of BioProtect)

Prostate cancer stands as the most common non-skin cancer detected in men and ranks as the second leading cause of male cancer-related deaths, following lung cancer. With a prevalence of 1 in 9 men receiving a prostate cancer diagnosis during their lifetime, over 1.4 million men are globally diagnosed annually. The course of prostate cancer treatment hinges on various factors including cancer growth rate, extent of spread, overall patient health, and potential treatment benefits or side effects. Treatment options like surgery or radiation may be recommended based on evolving test results. However, prostate radiation therapy often leads to a concerning issue – rectal toxicity, a consequence of the close proximity between the prostate and rectum. Despite advanced technology and precise planning, prostate movement during sessions exposes parts of the rectal wall to high radiation doses, resulting in rectal toxicity or proctitis. Hence, there is a strong need for a solution that protects the rectum from the detrimental effects of high-dose radiation. Now, a biodegradable balloon dramatically reduces the chance of rectal toxicity by protecting the adjacent healthy tissues from harmful radiation, thereby minimizing adverse procedural events.

BioProtect Ltd.’s (Tzur Yigal, Israel) BioProtect Balloon Implant System is an implantable, biodegradable balloon that creates a defined, enclosed distance to minimize radiation exposure to the rectum during prostate radiation therapy. Through its distinct design, the new generation balloon achieves up to 18mm separation between the rectal wall and the treatment area prior to initiating radiation therapy. The implantation process involves a minimally invasive, needle-free insertion technique for guiding the balloon using ultrasound with either local or general anesthesia. Once in place between the prostate and rectum, the balloon is filled with sterile saline and positioned to achieve its final, well-defined configuration.

By maintaining a consistent separation between the prostate and rectum, the balloon remains visible across various imaging modalities including CT, MRI, and ultrasound. It forms a protective barrier, allowing for safe radiation therapy. The balloon maintains its size and shape within the body throughout the radiation course, naturally biodegrading over time (typically within six months after implantation), thus negating the need for a separate removal procedure. The BioProtect Balloon Implant System has received clearance from the US FDA.

"We believe that our balloon has the potential to revolutionize rectal protection from toxicity during prostate cancer radiation therapy," said Itay Barnea, CEO of BioProtect. "Not only does it provide better protection to healthy organs, it also supports dose escalation and hypofractionation, which are leading trends in prostate cancer radiation therapy."

Related Links:
BioProtect Ltd. 

New
Gold Member
X-Ray QA Meter
T3 AD Pro
Radiation Therapy Treatment Software Application
Elekta ONE
LED-Based X-Ray Viewer
Dixion X-View
New
Mammo 3D Performance Kits
Mammo 3D Performance Kits

Print article

Channels

MRI

view channel
Image: MRI microscopy of mouse and human pancreas with respective histology demonstrating ability of DTI maps to identify pre-malignant lesions (Photo courtesy of Bilreiro C, et al. Investigative Radiology, 2024)

Pioneering MRI Technique Detects Pre-Malignant Pancreatic Lesions for The First Time

Pancreatic cancer is the leading cause of cancer-related fatalities. When the disease is localized, the five-year survival rate is 44%, but once it has spread, the rate drops to around 3%.... Read more

Ultrasound

view channel
Image: A transparent ultrasound transducer-based photoacoustic-ultrasound fusion probe, along with images of a rat’s rectum and a pig’s esophagus (Photo courtesy of POSTECH)

Transparent Ultrasound Transducer for Photoacoustic and Ultrasound Endoscopy to Improve Diagnostic Accuracy

Endoscopic ultrasound is a commonly used tool in gastroenterology for cancer diagnosis; however, it provides limited contrast in soft tissues and only offers structural information, which reduces its diagnostic... Read more

General/Advanced Imaging

view channel
Image: The results of the eight-view 3D CT reconstruction from a public dataset (Photo courtesy of Medical Physics, doi.org/10.1002/mp.12345)

AI Model Reconstructs Sparse-View 3D CT Scan With Much Lower X-Ray Dose

While 3D CT scans provide detailed images of internal structures, the 1,000 to 2,000 X-rays captured from different angles during scanning can increase cancer risk, especially for vulnerable patients.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.